MX2012003398A - Agonistas npr-b novedosos. - Google Patents

Agonistas npr-b novedosos.

Info

Publication number
MX2012003398A
MX2012003398A MX2012003398A MX2012003398A MX2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A
Authority
MX
Mexico
Prior art keywords
agonists
npr
new
new npr
unconventional
Prior art date
Application number
MX2012003398A
Other languages
English (en)
Spanish (es)
Inventor
Gerd Hummel
Frank Osterkamp
Heiko Hawlisch
Tobias Knaute
Ulf Reimer
Ulrich Reineke
Uwe Richter
Bernadett Simon
Markus Woischnik
Mark R Hellberg
Edgar Specker
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2012003398A publication Critical patent/MX2012003398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012003398A 2009-09-25 2010-09-23 Agonistas npr-b novedosos. MX2012003398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Publications (1)

Publication Number Publication Date
MX2012003398A true MX2012003398A (es) 2012-04-10

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR101768661B1 (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX354005B (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2557290C2 (enExample)
TW (2) TWI625126B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
KR101768661B1 (ko) 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
US20150045301A1 (en) * 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
EP2948165A2 (en) * 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
JP2020505476A (ja) * 2017-02-01 2020-02-20 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 眼科障害の治療のための化合物および組成物
AU2019288296B2 (en) * 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019379808C1 (en) * 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
CA3184145A1 (en) * 2020-06-12 2021-12-16 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006005140A2 (en) * 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
BRPI0709427A2 (pt) 2006-03-30 2011-07-12 Palatin Technologies Inc "construto cìclico, composição farmacêutica e uso de um composto
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
KR101768661B1 (ko) * 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Also Published As

Publication number Publication date
ZA201702958B (en) 2018-08-29
KR20170094564A (ko) 2017-08-18
TWI625126B (zh) 2018-06-01
US9982016B2 (en) 2018-05-29
US20130345394A1 (en) 2013-12-26
PH12012500562A1 (en) 2012-10-22
US20180334477A1 (en) 2018-11-22
AU2010298256A1 (en) 2012-04-12
TWI577384B (zh) 2017-04-11
RU2636738C2 (ru) 2017-11-28
CN105732767A (zh) 2016-07-06
US20160194357A1 (en) 2016-07-07
CA2773949A1 (en) 2011-03-31
KR101854820B1 (ko) 2018-05-04
EP2480247B1 (en) 2020-02-12
RU2557290C2 (ru) 2015-07-20
JP2017137362A (ja) 2017-08-10
MX370645B (es) 2019-12-19
AU2010298256B2 (en) 2015-08-13
US8546523B2 (en) 2013-10-01
WO2011038061A2 (en) 2011-03-31
KR20120091110A (ko) 2012-08-17
KR20180049198A (ko) 2018-05-10
AR078445A1 (es) 2011-11-09
JP5893561B2 (ja) 2016-03-23
US9169293B2 (en) 2015-10-27
CL2012000715A1 (es) 2012-11-30
US20170313743A1 (en) 2017-11-02
TW201630619A (zh) 2016-09-01
ZA201201630B (en) 2014-05-28
US20110077381A1 (en) 2011-03-31
UY32902A (es) 2011-02-28
RU2015124607A (ru) 2015-12-10
EP2480247A2 (en) 2012-08-01
JP6211032B2 (ja) 2017-10-11
CA2773949C (en) 2020-11-03
US9745344B2 (en) 2017-08-29
CN102548574A (zh) 2012-07-04
ZA201401625B (en) 2018-08-25
EP2480247A4 (en) 2013-09-04
US10196423B2 (en) 2019-02-05
TW201110974A (en) 2011-04-01
MX354005B (es) 2018-02-08
BR112012006579A2 (pt) 2016-11-22
RU2017139870A3 (enExample) 2019-05-16
WO2011038061A3 (en) 2011-07-28
RU2017139870A (ru) 2019-05-16
RU2012116531A (ru) 2013-10-27
CL2017001190A1 (es) 2017-12-01
JP2015131856A (ja) 2015-07-23
CN102548574B (zh) 2016-03-23
KR101768661B1 (ko) 2017-08-16
JP2013505937A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
MX2012003398A (es) Agonistas npr-b novedosos.
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
CY1122794T1 (el) Συνθεσεις αλφα-γαλακτοσιδασης
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
AR087070A1 (es) Proteinas de fusion liberadoras de relaxina y usos de las mismas
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
EA201171494A1 (ru) Миметики белка smac
CL2011002036A1 (es) Analogo peptidico doble agonista de los receptores de glp-1 y de glucagon.
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
IL216718A0 (en) Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
PH12013501656A1 (en) Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
ECSP12012181A (es) Nuevos péptidos y métodos para su preparación y uso
UA118167C2 (uk) Пептид та його застосування
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
PH12013500167A1 (en) Polypeptidic tyrosinase inhibitor
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
BR112012019042A2 (pt) "inibidores de serina protease tipo tripsina, e sua preparação e uso".
WO2011146922A3 (en) Materials and methods for treatment of inflammation
EP2819682A4 (en) TOPICAL GELS WITH ALPHA CONNEXIN C TERMINALS PEPTIDES (ACT)
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
CO6331291A2 (es) Peptidos de señalizacion de la crkl
WO2011100688A8 (en) Improved antagonists of muc1
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: SHIRE ORPHAN THERAPIES GMBH